Only more recently, the IL-6 tocilizumab has proven to be a further promising biologic approach capable to control disease manifestations also in cases unresponsive to TNF-α blockers; however, current literature on the role of IL-6 inhibition in TRAPS is quite limited (14). The gene discussed is IL6; the disease is TNF receptor 1-associated periodic fever syndrome.